

# Market Announcement

22 March 2022

---

## Australian Pharmaceutical Industries Limited (ASX: API) – Suspension from Quotation

### Description

The securities of Australian Pharmaceutical Industries Limited ('API') will be suspended from quotation at the close of trading on Tuesday, 22 March 2022 under Listing Rule 17.2, following lodgement of the Federal Court of Australia orders with ASIC approving the scheme of arrangement by which WFM Investments Pty Ltd, a wholly owned subsidiary of Wesfarmers Limited, will acquire all of the issued shares in API.

### Issued by

**Melissa Kostopoulos**

Compliance Adviser, Listings Compliance (Melbourne)



22 March 2022

James Gerraty  
General Manager ASX Listings Compliance  
Level 4, North Tower, Rialto  
525 Collins St  
Melbourne VIC 3000

Email: [James.Gerraty@asx.com.au](mailto:James.Gerraty@asx.com.au)  
Copy to: [Melissa.Kostopoulos@asx.com.au](mailto:Melissa.Kostopoulos@asx.com.au)

Dear James

**REQUEST FOR SUSPENSION – AUSTRALIAN PHARMACEUTICAL INDUSTRIES LIMITED**

**1. REQUEST FOR SUSPENSION**

API requests a suspension to be applied to our securities (ordinary shares – ASX code: API) under ASX Listing Rule 17.2 and set out below details of the request as required by ASX Listing Rule 17.2.

We request that the suspension commence on the close of trading today, this being 22 March 2022.

**2. REASON FOR SUSPENSION**

Australian Pharmaceutical Industries Limited has entered into a Scheme Implementation Deed with WFM Investments Pty Ltd (WFM Investments) and Wesfarmers Limited dated 8 November 2021, under which it is proposed that WFM Investments will acquire all the shares in API that it does not already own by way of a scheme of arrangement (Scheme).

The Scheme record date is 7.00 pm on 29 March 2022. To allow for the share register of API to settle, a suspension is requested as at close of trading today, this being 22 March 2022.

**3. LENGTH OF SUSPENSION**

API requests that the suspension lasts until API is delisted from the ASX. A separate application for delisting will be lodged with ASX.

**4. THE EVENT WE EXPECT TO HAPPEN THAT WILL END THE SUSPENSION**

API expects that the event to happen that will end the suspension will be the delisting of API from the ASX.

**5. OTHER INFORMATION**

API does not believe that any additional information needs to be advised to the market.

Yours faithfully

**Anne Mustow**  
General Counsel & Company Secretary  
Australian Pharmaceutical Industries Limited



Australian Pharmaceutical Industries Limited  
250 Camberwell Road Camberwell VIC 3124 Australia  
T: +61 3 8855 3000 [www.api.net.au](http://www.api.net.au) ACN 000 004 320